One of the most common questions patients ask after their thyroid eye disease (TED) has stabilized is the fear of or possibility of disease relapse (1). This is indeed a reasonable concern as emerging research shows that even after long periods of stability, thyroid eye disease, also known as Graves’ Eye Disease, can sometimes progress again (2). Understanding the underlying reasons behind the possibility and incidence of recurrence, who is at risk, and how to monitor changes can help patients and physicians respond early and protect both vision and quality of life.
The Typical Course of Thyroid Eye Disease Symptoms
Thyroid eye disease is an autoimmune inflammatory condition (the body’s immune system starts attacking itself) involving tissues around the eyes including muscles, fat, and connective tissue. TED disease often follows an archetypal course originally described in the literature, with an active inflammatory phase followed by a quieter, inactive phase (3). However, with more understanding of the disease, it is known that Thyroid Eye Disease frequently does not follow this course or timeline.
Active Phase
In its early phase, inflammation leads to symptoms such as:
- Eye bulging (proptosis)
- Eyelid retraction
- Redness and swelling
- Dryness or irritation
- Double vision (diplopia)
- Eye pressure or pain
Inactive Phase
Over time, the disease typically transitions from an active phase, characterized by inflammation and progression, to an inactive phase, where inflammation subsides and symptoms stabilize. Many patients assume that once TED becomes inactive, it will remain stable indefinitely. However, recent studies challenge that assumption.
What Research Shows About TED Progression After Stability
A recent retrospective study examined 107 patients with inactive thyroid eye disease who were followed over time without additional treatment (4). The findings showed that 17 out of 107 patients (15.9%) experienced progression, despite being classified as inactive at baseline. Patients who experienced progression showed measurable worsening in proptosis (eye bulging), eyelid positioning and clinical activity scores indicating renewed disease activity. This meant that nearly 1 in 6 patients with a previous history TED showed signs of worsening, highlighting that disease remission does not always guarantee permanent stability.
Reasons for the TED Recurrence
Several mechanisms may explain why TED can worsen even after years of dormancy.
1. Persistent Underlying Autoimmune Activity
TED is fundamentally an autoimmune disease, meaning the immune system mistakenly targets tissues in the orbit. Even if symptoms stabilize, the immune system may remain prone to reactivation. Small shifts in immune regulation, triggered by infections, stress, or changes in thyroid function may re-activate inflammation.
2. Smoking Is a Major Risk Factor
One of the strongest predictors of TED progression is smoking history. Smoking is an independently associated secondary risk factor of disease progression, even in inactive patients (5). Smoking contributes to increased orbital inflammation, poor oxygenation of tissues, increased oxidative stress and impaired response to treatment. Hence, smoking cessation is a strongly recommended measure for all patients with TED.
3. Longer Disease Duration Without Treatment
The above study also found that patients who had TED for more than 12 months without undertaking adequate treatment were more likely to experience progression. This suggests that untreated or undertreated inflammation, even if mild, may leave behind unresolved structural changes or immune activation that predispose to later worsening.
4. Structural Changes That Continue Over Time
Even after inflammation subsides, orbital tissues can continue to undergo remodeling. Fibrosis (scar formation), muscle thickening, and fat expansion can alter the mechanical balance of the orbit. These structural changes can contribute to worsening of eye bulging, eyelid position and eye alignment. This type of progressionmay not involve obvious inflammatory symptoms at first.
5. Thyroid Hormone and Fluctuations in Antibody Levels
Thyroid function and autoimmune antibody levels can fluctuate over time. Even small changes in thyroid-stimulating antibodies may re-trigger orbital inflammation. This is why maintaining stable thyroid function through routine follow up testing is critical, even years after initial diagnosis.
Signs of TED Recurrence
Patients should be aware of subtle changes that could signal renewed TED activity. These include increased eye bulging, new or worsening double vision, eyelids appearing more open or uneven, increased redness or swelling, increased dryness or irritation, increased eye pressure or discomfort and/or changes in vision clarity. These changes may develop gradually and should prompt evaluation by an eye specialist familiar with thyroid eye disease.
Why Monitoring Remains Important Even Years Later
Because progression can occur even after long stability, periodic monitoring is essential. Regular eye evaluations may include measurement of eye position (proptosis), eyelid position assessment, eye movement and alignment testing, visual acuity and color vision testing and imaging (CT or MRI) if needed. Early detection allows physicians to intervene before more serious complications develop.
Who Is Most at Risk for Late Progression?
Based on research and clinical experience, patients at higher risk include smokers or former smokers, patients with unstable thyroid hormone levels, those with high anti-thyroid antibody levels, individuals with untreated or inadequately treated TED, patients with longer disease duration and patients with prior moderate-to-severe disease, Having an understanding of personal risk factors helps guide monitoring and preventive strategies.
Dealing with TED Treatment and Management
The treatment module depends on the type and severity of disease progression (6). Options may include medical interventions such as corticosteroids, biologic therapies with monoclonal antibodies such as teprotumumab, immunosuppressive medications, and radiation therapy in select cases. These treatments target inflammation and immune-related activity. For structural change, the usual go-to option is surgical treatments including orbital decompression surgery, eye muscle surgery and eyelid repositioning surgery. These procedures address mechanical and structural consequences of disease progression.
Risks of Permanent Damage with Progression
It is important to be aware that recurrence does not necessarily mean progression. Many patients who experience progression can be successfully treated, especially when changes are detected early. Modern therapies, particularly targeted biologics, have significantly improved the ability to control disease progression and restore function. However, delayed treatment increases the risk of permanent structural changes, highlighting the importance of regular monitoring. While progression cannot always be prevented, several steps can significantly reduce risk:
- Quit smoking: smoking is one of the strongest modifiable risk factors.
- Maintain stable thyroid function: work closely with your endocrinologist to keep thyroid hormone levels stable.
- Attend regular follow-up eye exams: even if symptoms are stable, periodic evaluation helps detect subtle changes early.
- Report on new symptoms promptly: early treatment leads to better outcomes.
- Follow treatment recommendations: complete recommended medical or surgical therapies when indicated.
Schedule Your Appointment Today for Early Intervention
Though TED often stabilizes but stability does not always mean permanent remission. Research shows that approximately 16% of patients with inactive thyroid eye disease may experience progression, especially those with secondary risk factors such as smoking or a longer course of disease. But the good news is that modern treatments are highly effective, and careful monitoring allows early intervention.
If you notice a recurrence in symptoms such as eye discomfort, swelling, redness, bulging, double vision, or changes in eyelid position especially if you indulge in secondary risk factors such as smoking, do schedule an appointment with Dr. Raymond Douglas without delay.
References
- Shah, S. S. & Patel, B. C. in StatPearls   (2025).
- Oustabassidis, E., Murphy, N., Turner, H. E. & Norris, J. H. Puzzling Late Relapse of Thyroid Eye Disease: A Case Series. JCEM Case Rep 3, luaf051 (2025). https://doi.org/10.1210/jcemcr/luaf051
- Men, C. J., Kossler, A. L. & Wester, S. T. Updates on the understanding and management of thyroid eye disease. Ther Adv Ophthalmol 13, 25158414211027760 (2021). https://doi.org/10.1177/25158414211027760
- Qi, L.et al. Predictive model for the progression of inactive thyroid eye disease: a retrospective study. Endocrine 84, 533-540 (2024). https://doi.org/10.1007/s12020-023-03582-6
- Thornton, J., Kelly, S. P., Harrison, R. A. & Edwards, R. Cigarette smoking and thyroid eye disease: a systematic review. Eye (Lond) 21, 1135-1145 (2007). https://doi.org/10.1038/sj.eye.67026036 Dhaliwal, N. K. & Razzaq, L. The Management of Thyroid Eye Disease: From Current Practice to Future Perspectives. Cureus17, e86483 (2025). https://doi.org/10.7759/cureus.86483
English 
Spanish